Cardiac fibrosis is a pathological condition characterized by the excessive accumulation of collagen fibers in the heart tissue, leading to increased stiffness and impaired function of the heart. This condition often results from prolonged or chronic cardiovascular diseases, such as hypertension or chronic inflammation. As the collagen deposits replace normal heart tissue, the heart's ability to pump blood efficiently is compromised, potentially leading to heart failure. Cardiac fibrosis is a significant concern in the field of cardiology, as it represents a key factor in the progression of various heart disorders. Understanding the molecular mechanisms underlying cardiac fibrosis is crucial for developing targeted therapeutic interventions aimed at preventing or reversing this detrimental process and preserving heart function. Ongoing research in this area seeks to unravel the complexities of cardiac fibrosis, paving the way for innovative treatments to mitigate its impact on cardiovascular health.
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain
Title : Innovative mechanisms, consequences and therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Comprehensive surgical revascularization for rapidly worsening ischemic heart failure
Deepak Puri, Max Healthcare, India